Submit an application to add a new pre-filled syringe manufacturing filler to the EYLEA HD BLA
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Oct 2025
- Due
- 31 Jan 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company is planning to submit by January 2026 an application to include a new pre-filled syringe manufacturing filler in the EYLEA HD BLA.”
What we found
Evidence strength A What the grades mean
A 10-K filed 2026-02-04 states the company submitted a PFS application naming a new manufacturer in December 2025, before the January 2026 deadline.
-
A Regeneron Pharmaceuticals 10-K filed 2026-02-04
“In December 2025, the Company submitted a regulatory application seeking approval of the EYLEA HD pre-filled syringe using a new manufacturer.” ✓ confirmed on the page
Market reaction: the shares moved +3.3% against the S&P 500 over the three sessions around the disclosure (3 Feb 2026 to 6 Feb 2026). What this measures
Checked 11 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Application adding new pre-filled syringe filler to EYLEA HD BLA
- Where
- United States
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-REGN-006353 · Corrections policy